Surgery Partners (SGRY) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Surgery Partners (NASDAQ:SGRY) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning.
According to Zacks, “Surgery Partners, Inc. is a healthcare services company. The Company’s outpatient delivery model focused on providing solutions for surgical and related ancillary care in support of its patients and physicians. Its operating segment consists of Surgical Facility Services segment, Ancillary Services segment and Optical Services segment. Surgery Partners, Inc. is based in Nashville, Tennessee. “
Several other research firms have also commented on SGRY. BidaskClub lowered shares of Surgery Partners from a hold rating to a sell rating in a research note on Wednesday, September 12th. Bank of America raised shares of Surgery Partners from a neutral rating to a buy rating in a research note on Tuesday, September 18th. ValuEngine raised shares of Surgery Partners from a buy rating to a strong-buy rating in a research note on Thursday, November 1st. Finally, UBS Group assumed coverage on shares of Surgery Partners in a research note on Thursday, November 15th. They set a neutral rating and a $15.00 price objective on the stock. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Surgery Partners presently has an average rating of Buy and a consensus target price of $18.29.
Surgery Partners (NASDAQ:SGRY) last announced its earnings results on Wednesday, November 7th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The company had revenue of $443.90 million for the quarter, compared to the consensus estimate of $440.38 million. Surgery Partners had a negative net margin of 5.55% and a negative return on equity of 1.68%. The company’s revenue for the quarter was up 44.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.02) EPS. Research analysts expect that Surgery Partners will post -0.75 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. NN Investment Partners Holdings N.V. lifted its stake in shares of Surgery Partners by 1.3% in the third quarter. NN Investment Partners Holdings N.V. now owns 5,597,607 shares of the company’s stock worth $92,361,000 after buying an additional 73,806 shares in the last quarter. Clearbridge Investments LLC lifted its stake in shares of Surgery Partners by 4.6% in the third quarter. Clearbridge Investments LLC now owns 3,250,407 shares of the company’s stock worth $53,632,000 after buying an additional 143,561 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Surgery Partners by 1.2% in the third quarter. Vanguard Group Inc. now owns 1,566,343 shares of the company’s stock worth $25,845,000 after buying an additional 18,336 shares in the last quarter. Vanguard Group Inc lifted its stake in shares of Surgery Partners by 1.2% in the third quarter. Vanguard Group Inc now owns 1,566,343 shares of the company’s stock worth $25,845,000 after buying an additional 18,336 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in shares of Surgery Partners by 3.6% in the second quarter. BlackRock Inc. now owns 1,338,176 shares of the company’s stock worth $19,939,000 after buying an additional 46,111 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.
About Surgery Partners
Surgery Partners, Inc, through its subsidiaries, operates surgical facilities in the United States. The company operates through three segments: Surgical Facility Services, Ancillary Services, and Optical Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management.
Further Reading: How to interpret a stock’s beta number
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.